November 2, 2018 10:41 AM EDT

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

Amber Tong

J&J’s 5-year acquaintanceship with OSE Immunotherapeutics has come to an end as the pharma giant decided it doesn’t want the CD28 antagonist FR104 after all …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

Amber Tong

Sign up to read this article for free.

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line

J&J dumps PhII-ready CD28 au­toim­mune as­set, re­turns rights to French part­ner

Amber Tong

Sign up to read this article for free.

more like this

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

Ex­clu­sive: First-of-its-kind in­fant DNA ed­it leads to ap­par­ent cure in dis­ease that set back field 25 years ago

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

J&J dumps PhII-ready CD28 autoimmune asset, returns rights to French partner

Vir’s early T cell engager data offer first look at cancer pivot, stock jumps

ARCH, F-Prime and Mubadala pump $200M into former Denali programs

Updated: Galapagos to split into two companies, slash headcount as it eyes turnaround

Sana’s stock soars on new cell therapy data; UniQure’s $75M offering

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Every FDA drug approval from 2024: Fewer nods, but long-awaited treatments cross the finish line